ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Frequency and Types of Pharmacist Interventions and Risk Assessments Occurring During the 12-Month Transafe Rx Randomized Controlled Trial

H. M. Gonzales, J. N. Fleming, D. J. Taber

MUSC, Charleston, SC

Meeting: 2021 American Transplant Congress

Abstract number: 388

Keywords: Kidney, Kidney transplantation

Topic: Clinical Science » Ethics » Psychosocial and Treatment Adherence

Session Information

Session Name: A Penny for Your Thoughts: the Economics and Psychosocial Aspects of Transplant

Session Type: Rapid Fire Oral Abstract

Date: Tuesday, June 8, 2021

Session Time: 6:00pm-7:00pm

 Presentation Time: 6:30pm-6:35pm

Location: Virtual

*Purpose: Clinical pharmacists have unique education and training to identify and mitigate medication (med) safety issues in high-risk populations, such as kidney transplant (KTX). The primary aim of the TRANSAFE Rx study was to assess the efficacy of a pharmacist-led, mHealth-based intervention at improving med safety issues in KTX, as compared to usual care.

*Methods: This was an a priori planned secondary analysis of detailed interventions and risk assessments that occurred during a 12-month, parallel arm, 1:1 randomized controlled clinical trial in adult KTX 6 to 36 months post-transplant (NCT03247322). This intervention previously demonstrated reduced hospitalizations and adverse drug events. All patients received usual post-transplant care, while those randomized to the intervention arm received supplemental clinical pharmacist-led medication therapy monitoring and management, via a smartphone-enabled mHealth app, integrated with risk-based televisits and home-based blood pressure and blood glucose monitoring. The clinical pharmacist conducted weekly risk assessments and recorded both pharmacological and nonpharmacological interventions performed throughout the study.

*Results: 136 patients were enrolled, 68 were randomized in the intervention arm and included in this secondary analysis. The mean age at baseline was 50.2 years, 51.5% of patients were male and 58.8% were black. The primary etiologies of ESRD were hypertension (92.6%) and diabetes (27.9%); 85.3% of patients were on dialysis at time of transplant. During the 12-month follow-up, the most common pharmacist intervention types included medication reconciliation (N=213) and patient education (N=144, Figure 1). Medication alterations, including additions, deletions, dose adjustments, schedule changes, interval changes, and dosage form changes, were also common. Medication reconciliation, study technology-related issues, prescription refills, and facilitating medication access largely remained consistent throughout the 12-month study period, while patient education and medication changes trended downward from Month 1 to Month 12 (Figure 2). From baseline to end-of-study, we observed an approximately 15% decrease in high-risk patients and a corresponding 15% increase in medium or low-risk patients (Figure 3).

*Conclusions: A pharmacist-led mHealth based intervention may increase opportunities for both pharmacological and nonpharmacological interventions and reduce the number of high-risk patients in the KTX population.

 border=

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Gonzales HM, Fleming JN, Taber DJ. Frequency and Types of Pharmacist Interventions and Risk Assessments Occurring During the 12-Month Transafe Rx Randomized Controlled Trial [abstract]. Am J Transplant. 2021; 21 (suppl 3). https://atcmeetingabstracts.com/abstract/frequency-and-types-of-pharmacist-interventions-and-risk-assessments-occurring-during-the-12-month-transafe-rx-randomized-controlled-trial/. Accessed May 9, 2025.

« Back to 2021 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences